-
1.发明授权Hypercoagulability comparative determinants obtained using detection systems with variable force-induced energy inputs 失效使用具有可变力诱导能量输入的检测系统获得的高凝状态比较决定因素
公开(公告)号：US5783447A
公开(公告)日：1998-07-21
申请号：US731177
申请日：1996-10-02
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N2800/52 , Y10T436/119163
摘要： A method of analyzing samples of whole blood from a patient is disclosed which involves determining whether or not there is a significant difference or change in the comparative determinants of hypercoagulability in the sample. The comparative determinants are derived using two or more different detection systems, or two or more components of a single detection system, especially two or more probes, which provide variable force-induced energy inputs to the samples being measured in order to identify the presence of incipiency of a symptomatic or asymptomatic pathology caused by, or leading to, differences or changes in hypercoagulability.
摘要翻译： 公开了分析来自患者的全血样品的方法，其涉及确定样品中高凝状态的比较决定因素是否存在显着差异或变化。 比较决定因素是使用两个或多个不同的检测系统，或单个检测系统的两个或更多个成分，特别是两个或更多个探针，其被提供给被测量样品的可变力诱导能量输入，以便识别 由于高凝状态的差异或变化引起的或有导致的症状性或无症状性病变的现象。
-
2.发明授权Process for treating a warm-blooded animal with an antineoplastic/antime-tastatic effective composition 失效用抗肿瘤/抗肿瘤有效组合物治疗温血动物的方法
公开(公告)号：US4833132A
公开(公告)日：1989-05-23
申请号：US030283
申请日：1987-03-23
IPC分类号： A61K31/42 , A61K31/505 , A61K31/635
CPC分类号： A61K31/505 , A61K31/42 , A61K31/635
摘要： There is disclosed a process for treating a warm-blooded animal wherein there is administered to the warm-blooded animal a therapeutically effective amount of composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof. The composition is useful to treat a fibrosarcoma (SAD.sub.2) tumor in warm-blooded animals.
摘要翻译： 公开了一种治疗温血动物的方法，其中向温血动物施用治疗有效量的组合物，其选自5-甲基-3-磺酰胺基异恶唑，5-甲基-3 （3,4,5-三甲氧基苄基）嘧啶，2,4-二氨基-5-（3,4,5-三甲氧基苄基）嘧啶的盐与具有药学上可接受的碱的2,4-二氨基-5- 药学上可接受的酸及其混合物。 该组合物可用于治疗温血动物中的纤维肉瘤（SAD2）肿瘤。
-
公开(公告)号：US08530455B2
公开(公告)日：2013-09-10
申请号：US12851041
申请日：2010-08-05
IPC分类号： A61K31/585
CPC分类号： G01N33/86 , A61K31/366 , G01N33/5302 , G01N2800/22 , G01N2800/50
摘要： Glucono-delta-lactone (GDL) can be used to mediate the human blood coagulation process. In particular, GDL can be used in an assay to determine an individual's risk potential for accelerated blood clotting or as a treatment for conditions related to accelerated clotting potential and/or inflammatory states.
摘要翻译： 葡萄糖酸-δ-内酯（GDL）可用于介导人血液凝固过程。 特别地，GDL可用于测定以确定个体加速血液凝固的潜在风险，或作为与加速凝血潜能和/或炎症状态相关的病症的治疗。
-
公开(公告)号：US4632920A
公开(公告)日：1986-12-30
申请号：US655079
申请日：1984-09-27
IPC分类号： A61K31/505 , A61K31/635
CPC分类号： A61K31/635 , A61K31/505
摘要： There is disclosed a process for treating a warm-blooded animal following burn injury wherein there is administered to the warm-blooded animal a therapeutically effect amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrmidine with a pharmaceutically acceptable acid and mixtures thereof.
摘要翻译： 公开了一种在烧伤后治疗温血动物的方法，其中向温血动物施用治疗有效量的选自5-甲基-3-磺胺基异恶唑，5的盐 （3,4,5-三甲氧基苄基）嘧啶，2,4-二氨基-5-（3,4,5-三甲氧基苄基）嘧啶的盐， ）嘧啶与其药学上可接受的酸及其混合物。
-
公开(公告)号：US06514766B2
公开(公告)日：2003-02-04
申请号：US09915198
申请日：2001-07-25
IPC分类号： G01N3386
摘要： Methods for enhancing the value of the traditional erythrocyte sedimentation rate (ESR) test are provided by including an ESR-modifying agent, such as a metal ion, in the sample. Results of the resulting modified ESR are correlated with the health status of the animal.
-
6.发明授权Method of determining the existence and/or the monitoring of a pathological condition in a mammal 失效确定哺乳动物病理状态的存在和/或监测的方法
公开(公告)号：US4705756A
公开(公告)日：1987-11-10
申请号：US734799
申请日：1985-05-16
IPC分类号： G01N33/50 , G01N33/53 , G01N33/569 , G01N33/574 , G01N33/68 , G01N33/86
CPC分类号： G01N33/50 , G01N33/569 , G01N33/56911 , G01N33/57488 , G01N33/68 , G01N33/86 , G01N2800/52
摘要： A method of testing a cellular hematologic fluid derived from a mammal to determine the existence in the mammal of a pathological state or condition wherein an immunomodulator is admixed with the cellular hematologic fluid of the mammal and a reaction parameter determined and compared with known reaction parameters of cellular hematologic fluids of mammals of known healthy states to like immunomodulator. In a preferred embodiment of the present invention, the reaction parameter is a clotting parameter as determined as fibrin levels.
摘要翻译： 一种测试源自哺乳动物的细胞血液学液体的方法，以确定在哺乳动物中存在的病理状态或病症，其中将免疫调节剂与哺乳动物的细胞血液学液体混合，并将反应参数与已知的反应参数 已知健康状态的哺乳动物的细胞血液学类似免疫调节剂。 在本发明的优选实施方案中，反应参数是如纤维蛋白水平所确定的凝血参数。
-
7.发明授权Process for prolonging recalcification, prothrombin and thrombin times of plasma 失效延长血浆再钙化，凝血酶原和凝血酶时间的方法
公开(公告)号：US4632919A
公开(公告)日：1986-12-30
申请号：US655145
申请日：1984-09-27
IPC分类号： A61K31/505 , A61K31/635
CPC分类号： A61K31/635 , A61K31/505
摘要： There is disclosed a process for prolonging recalcification, prothrombin and thrombin times of human plasma which comprises administering to a warm-blooded animal a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.
摘要翻译： 公开了延长人血浆的再钙化，凝血酶原和凝血酶时间的方法，其包括向温血动物施用选自5-甲基-3-磺胺基异恶唑，5-甲基-3- 亚磺酰氨基异恶唑与药学上可接受的碱，2,4-二氨基-5-（3,4,5-三甲氧基苄基）嘧啶，2,4-二氨基-5-（3,4,5-三甲氧基苄基）嘧啶的盐与药学上 可接受的酸及其混合物。
-
8.发明授权Comparative determinants of viscosity in body fluids obtained with probes providing increased sensitivity 失效使用提供增加灵敏度的探针获得的体液粘度的比较决定因素
公开(公告)号：US5792660A
公开(公告)日：1998-08-11
申请号：US720675
申请日：1996-10-02
IPC分类号： G01N11/16 , G01N33/487 , G01N33/49 , G01N33/86
CPC分类号： G01N33/4905 , G01N11/16 , Y10T436/119163
摘要： This invention involves a method of analyzing a body fluid such as blood from a patient to determine whether or not there is a significant difference or change in the comparative determinants of viscosity in the body fluid sample, the comparative determinants being derived using a probe which provides increased sensitivity and corresponding improved relative viscosity values when used together with a suitable viscosity device, in order to identify the presence or incipiency of a symptomatic or asymptomatic pathology caused by or leading to said differences or changes in viscosity.
摘要翻译： 本发明涉及一种分析来自患者的体液如血液的方法，以确定体液样品中粘度的比较决定因素是否存在显着差异或变化，比较决定因素是使用提供的 当与合适的粘度装置一起使用时，提高灵敏度和相应改善的相对粘度值，以便鉴定由所述差异或粘度变化引起的或导致所述差异或粘度变化的症状性或无症状性病变的存在或起始。
-
9.发明授权Method for determining the existence and/or the monitoring of a pathological condition in a mammal and a test kit therefor 失效用于确定哺乳动物及其测试试剂盒的病态的存在和/或监测的方法
公开(公告)号：US4900679A
公开(公告)日：1990-02-13
申请号：US236039
申请日：1988-08-23
IPC分类号： G01N33/50 , G01N33/569 , G01N33/574 , G01N33/86
CPC分类号： G01N33/57488 , G01N33/50 , G01N33/56911 , G01N33/56988 , G01N33/86 , G01N2800/52
摘要： There is disclosed a method of testing, and a kit therefor, a cellular hematologic fluid derived from a mammal to determine the existence in the mammal of a pathological state or condition wherein an immunomodulator is admixed with the cellular hematologic fluid of the mammal and a reaction parameter determined and compared with known reaction parameters of cellular hematologic fluids of mammals of known healthy states to like immunomodulator. In a preferred embodiment of the present invention, the reaction parameter is a clotting parameter as determined as fibrin levels.
摘要翻译： 公开了一种测试方法，其试剂盒来自哺乳动物的细胞血液学液体，以确定在哺乳动物中存在的病理状态或病症，其中将免疫调节剂与哺乳动物的细胞血液学液体混合，并进行反应 参数确定并与已知健康状态的哺乳动物的细胞血液学液体的已知反应参数进行比较，以与类似的免疫调节剂相似。 在本发明的优选实施方案中，反应参数是如纤维蛋白水平所确定的凝血参数。
-
10.发明授权Method for determining the existance and/or the monitoring of a pathological condition in a mammal 失效用于确定哺乳动物病理状况的存在和/或监测的方法
公开(公告)号：US4814247A
公开(公告)日：1989-03-21
申请号：US34101
申请日：1987-03-16
IPC分类号： G01N33/50 , G01N33/569 , G01N33/574 , G01N33/86
CPC分类号： G01N33/86 , G01N33/50 , G01N33/56911 , G01N33/56988 , G01N33/57488 , G01N2800/52
摘要： There is disclosed a method of testing a cellular hematologic fluid derived from a mammal to determine the existence in the mammal of a pathological state or condition wherein an immunomodulator is admixed with the cellular hematologic fluid of the mammal and a reaction parameter determined and compared with known reaction parameters of cellular hematologic fluids of mammals of known healthy states to like immunomodulator. In a preferred embodiment of the present invention, the reaction parameter is a clotting parameter as determined as fibrin levels.
摘要翻译： PCT No.PCT / US86 / 01075 Sec。 371日期1987年3月16日 102（e）1987年3月16日PCT PCT日期：1986年5月16日PCT公开 出版物WO86 / 06840 日本公开了1986年11月20日的日期。公开了一种测试来自哺乳动物的细胞血液学液体的方法，以确定在哺乳动物中存在的病理状态或病症，其中将免疫调节剂与哺乳动物的细胞血液学液体混合， 确定反应参数并与已知健康状态的哺乳动物的细胞血液液体的已知反应参数进行比较，以与免疫调节剂相似。 在本发明的优选实施方案中，反应参数是如纤维蛋白水平所确定的凝血参数。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.014 秒)
